Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article
Advertisement

Resource and Technical AdvanceIn-Press PreviewClinical ResearchHematologyOncology Open Access | 10.1172/jci.insight.209042

Plasma proteins associated with chronic graft-versus-host disease organ involvement

Stephanie J. Lee,1 Corey Cutler,2 Ningxin Ma,1 Timothy W. Randolph,1 George L. Chen,3 Joseph Pidala,4 Betty K. Hamilton,5 Carrie L. Kitko,6 Sally Arai,7 Najla El Jurdi,8 Lynn Onstad,1 Motoko Koyama,1 Catherine J. Lee,1 Sophie Paczesny,9 and Geoffrey R. Hill1

1Fred Hutchinson Cancer Center, Seattle, United States of America

2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America

3The University of Texas MD Anderson Cancer Center, Houston, United States of America

4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America

5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America

6Vanderbilt University Medical Center, Nashville, United States of America

7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America

8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America

9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America

Find articles by Lee, S. in: PubMed | Google Scholar |

1Fred Hutchinson Cancer Center, Seattle, United States of America

2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America

3The University of Texas MD Anderson Cancer Center, Houston, United States of America

4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America

5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America

6Vanderbilt University Medical Center, Nashville, United States of America

7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America

8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America

9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America

Find articles by Cutler, C. in: PubMed | Google Scholar |

1Fred Hutchinson Cancer Center, Seattle, United States of America

2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America

3The University of Texas MD Anderson Cancer Center, Houston, United States of America

4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America

5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America

6Vanderbilt University Medical Center, Nashville, United States of America

7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America

8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America

9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America

Find articles by Ma, N. in: PubMed | Google Scholar

1Fred Hutchinson Cancer Center, Seattle, United States of America

2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America

3The University of Texas MD Anderson Cancer Center, Houston, United States of America

4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America

5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America

6Vanderbilt University Medical Center, Nashville, United States of America

7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America

8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America

9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America

Find articles by Randolph, T. in: PubMed | Google Scholar |

1Fred Hutchinson Cancer Center, Seattle, United States of America

2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America

3The University of Texas MD Anderson Cancer Center, Houston, United States of America

4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America

5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America

6Vanderbilt University Medical Center, Nashville, United States of America

7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America

8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America

9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America

Find articles by Chen, G. in: PubMed | Google Scholar

1Fred Hutchinson Cancer Center, Seattle, United States of America

2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America

3The University of Texas MD Anderson Cancer Center, Houston, United States of America

4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America

5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America

6Vanderbilt University Medical Center, Nashville, United States of America

7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America

8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America

9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America

Find articles by Pidala, J. in: PubMed | Google Scholar

1Fred Hutchinson Cancer Center, Seattle, United States of America

2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America

3The University of Texas MD Anderson Cancer Center, Houston, United States of America

4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America

5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America

6Vanderbilt University Medical Center, Nashville, United States of America

7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America

8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America

9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America

Find articles by Hamilton, B. in: PubMed | Google Scholar

1Fred Hutchinson Cancer Center, Seattle, United States of America

2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America

3The University of Texas MD Anderson Cancer Center, Houston, United States of America

4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America

5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America

6Vanderbilt University Medical Center, Nashville, United States of America

7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America

8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America

9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America

Find articles by Kitko, C. in: PubMed | Google Scholar

1Fred Hutchinson Cancer Center, Seattle, United States of America

2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America

3The University of Texas MD Anderson Cancer Center, Houston, United States of America

4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America

5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America

6Vanderbilt University Medical Center, Nashville, United States of America

7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America

8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America

9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America

Find articles by Arai, S. in: PubMed | Google Scholar

1Fred Hutchinson Cancer Center, Seattle, United States of America

2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America

3The University of Texas MD Anderson Cancer Center, Houston, United States of America

4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America

5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America

6Vanderbilt University Medical Center, Nashville, United States of America

7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America

8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America

9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America

Find articles by El Jurdi, N. in: PubMed | Google Scholar

1Fred Hutchinson Cancer Center, Seattle, United States of America

2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America

3The University of Texas MD Anderson Cancer Center, Houston, United States of America

4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America

5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America

6Vanderbilt University Medical Center, Nashville, United States of America

7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America

8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America

9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America

Find articles by Onstad, L. in: PubMed | Google Scholar

1Fred Hutchinson Cancer Center, Seattle, United States of America

2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America

3The University of Texas MD Anderson Cancer Center, Houston, United States of America

4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America

5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America

6Vanderbilt University Medical Center, Nashville, United States of America

7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America

8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America

9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America

Find articles by Koyama, M. in: PubMed | Google Scholar

1Fred Hutchinson Cancer Center, Seattle, United States of America

2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America

3The University of Texas MD Anderson Cancer Center, Houston, United States of America

4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America

5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America

6Vanderbilt University Medical Center, Nashville, United States of America

7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America

8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America

9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America

Find articles by Lee, C. in: PubMed | Google Scholar

1Fred Hutchinson Cancer Center, Seattle, United States of America

2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America

3The University of Texas MD Anderson Cancer Center, Houston, United States of America

4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America

5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America

6Vanderbilt University Medical Center, Nashville, United States of America

7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America

8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America

9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America

Find articles by Paczesny, S. in: PubMed | Google Scholar |

1Fred Hutchinson Cancer Center, Seattle, United States of America

2Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, United States of America

3The University of Texas MD Anderson Cancer Center, Houston, United States of America

4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, United States of America

5Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America

6Vanderbilt University Medical Center, Nashville, United States of America

7Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, United States of America

8Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, United States of America

9Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, United States of America

Find articles by Hill, G. in: PubMed | Google Scholar

Published July 28, 2026 - More info

JCI Insight. https://doi.org/10.1172/jci.insight.209042.
Copyright © 2026, Lee et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published July 28, 2026 - Version history
View PDF
Abstract

BACKGROUND. Prior studies identified plasma proteins associated with chronic graft-versus-host disease (cGVHD). The goal of this cross-sectional study was to evaluate whether plasma biomarkers were associated with specific organ manifestations to help guide treatment choice.

METHODS. Plasma proteins were measured in patients with cGVHD (n = 695) from Chronic GVHD Consortium studies. Correlations of plasma protein levels with individual organ involvement were tested with p≤0.05 considered significant after Benjamini-Hochberg adjustment and adjustment for five baseline clinical variables.

RESULTS. Median time from cGVHD diagnosis to blood draw was 0.9 months (IQR 0.1–9.5). Donors were 50% HLA-matched unrelated, 32% matched related and the remainder were umbilical cord blood, haploidentical or mismatched unrelated donors. Methotrexate and calcineurin inhibitor acute GVHD (aGVHD) prophylaxis was used in 53% of patients. Overall, 326 (47%) had moderate and 244 (35%) had severe cGVHD with the following organ involvement at time of blood draw: skin (67%), mouth (60%), eye (49%), joint (34%), GI (31%), lung (23%), and liver (17%). After adjustment for batch effects and patient and transplant characteristics, fourteen plasma proteins were associated with organ involvement with independent AUCs of 0.7-0.8. All organs except eye were associated with at least one biomarker. However, no combination of plasma proteins improved model fit after adjusting for patient and transplant clinical variables.

CONCLUSION. Correlations between plasma proteins and organ involvement were identified but are not actionable. Our future investigations will focus on more granular and immediately proximal determinants of cGVHD biology in both blood and tissue.

Supplemental material

View

Version history
  • Version 1 (July 28, 2026): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts